The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular edema

被引:12
|
作者
Cicinelli, Maria Vittoria [1 ,2 ]
Rosenblatt, Amir [3 ,4 ]
Grosso, Domenico [2 ]
Zollet, Piero [2 ]
Capone, Luigi [2 ]
Rabiolo, Alessandro [2 ,5 ]
Lattanzio, Rosangela [2 ]
Loewenstein, Anat [3 ,4 ]
Bandello, Francesco [1 ,2 ]
机构
[1] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy
[2] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy
[3] Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Gloucestershire Hosp NHS Fdn Trust, Dept Ophthalmol, Cheltenham, Glos, England
关键词
VITREOUS INSERTS; MANAGEMENT; RANIBIZUMAB; EFFICACY; BENEFIT; RETINA; 3-YEAR; SAFETY;
D O I
10.1038/s41433-020-01373-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background/Objectives To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO). Methods Retrospective cohort study including pseudophakic patients with previously treated DMO, undergone one or more DEX injections before FAc. Functional and morphologic response to DEX was defined based on the best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes after the first DEX, respectively. Steroid-response was defined as intraocular pressure (IOP) elevation >= 5 mmHg or IOP > 21 mmHg after any previous DEX exposure. Pairwise comparisons for BCVA, CMT, and IOP after FAc were performed with linear mixed models and a repeated-measure design. Results Forty-four eyes of 33 patients were included. Patients were shifted to FAc after a mean +/- standard deviation of 4.6 +/- 3.2 DEX injections. Overall, BCVA and CMT improved during the first 12 months after switching to FAc (p = 0.04 and p < 0.001, respectively). Only eyes with a good morphologic response to DEX had a significant CMT reduction after FAc (p < 0.001), while no significant relationship was found between BCVA improvement after DEX and after FAc. IOP elevation occurred in 9 eyes (20%) following DEX implant. These eyes carried a 20-fold increased risk of having an IOP rise after FAc (p < 0.001), with a non-linear relationship between the IOP increase after DEX and the one after FAc. Conclusion The response to previous DEX may anticipate the morphologic response to subsequent FAc. Eyes with steroid-induced IOP elevation after DEX are at a high risk of IOP increase after FAc. The visual response after FAc was not associated with the visual response to previous steroids, indicating that FAc may have a role also in patients refractory to DEX implant.
引用
收藏
页码:3232 / 3242
页数:11
相关论文
共 50 条
  • [21] Real-world experience with fluocinolone acetonide intravitreal implant in patients with diabetic macular edema
    Capone, Luigi
    Airaghi, Pietro
    Aragona, Pasquale
    Castellino, Nicolo
    Cicinelli, Maria Vittoria
    Ciucci, Francesco
    Coppola, Michele
    De Gaetano, Cristiano
    Lattanzio, Rosangela
    Lorusso, Massimo
    Maceroni, Martina
    Malvasi, Maria Elena
    Marco, Luisa
    Marraffa, Michele
    Martini, Gaia
    Mastropasqua, Rodolfo
    Minnella, Angelo Maria
    Nikolopulou, Eleni
    Ortisi, Elina
    Pacella, Elena
    Papa, Vincenzo
    Pennesi, Claudio
    Reibaldi, Michele
    Rizzo, Stanislao
    Toto, Lisa
    Trombetta, Luigi
    Bandello, Francesco
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2024,
  • [22] Efficacy of dexamethasone intravitreal implant in diabetic macular edema
    Bonnin, Sophie
    Dupas, Benedicte
    Perol, Julien
    Erginay, Ali
    Tadayoni, Ramin
    Massin, Pascale
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [23] Dexamethasone intravitreal implant in the treatment of diabetic macular edema
    Dugel, Pravin U.
    Bandello, Francesco
    Loewenstein, Anat
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 1321 - 1335
  • [24] Intravitreal Dexamethasone Implant for Persistent Diabetic Macular Edema
    Alagoz, Cengiz
    Gunes, Hasan
    Baz, Okkes
    Yuksel, Kemal
    Yilmaz, Ihsan
    Yazici, Ahmet Taylan
    Demirok, Ahmet
    OPHTHALMOLOGICA, 2014, 232 : 18 - 18
  • [25] Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
    William Fusi-Rubiano
    Rebecca R. Blow
    Mark Lane
    Rupal Morjaria
    Alastair K. Denniston
    Ophthalmology and Therapy, 2020, 9 : 205 - 205
  • [26] The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema
    Merrill, Pauline T.
    Holekamp, Nancy
    Roth, Daniel
    Kasper, Jonathan
    Grigorian, Ruben
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2023, 248 : 16 - 23
  • [27] Iluvien (Fluocinolone Acetonide 0.19mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
    Fusi-Rubiano, William
    Blow, Rebecca R.
    Lane, Mark
    Morjaria, Rupal
    Denniston, Alastair K.
    OPHTHALMOLOGY AND THERAPY, 2018, 7 (02) : 293 - 305
  • [28] Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema
    Morozova, Christine
    Humayun, Lucas L.
    Kasper, Jonathan
    Morozov, Andy
    Tabandeh, Homayoun
    Boyer, David S.
    Dayani, Pouya N.
    Rahhal, Firas M.
    JOURNAL OF VITREORETINAL DISEASES, 2024, 8 (04) : 394 - 400
  • [29] River Study - Registry Data on the Use of Intravitreal Fluocinolone Acetonide Implant for Diabetic Macular Edema in Portugal
    Penas, Susana
    Pessoa, B.
    Teixeira, C.
    Sousa, J. P.
    Ruao, M.
    Meireles, A.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2023, 33 (01) : 7 - 8
  • [30] Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
    Massa, Horace
    Nagar, Anindyt M.
    Vergados, Athanasios
    Dadoukis, Panagiotis
    Patra, Sudeshna
    Panos, Georgios D.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (01) : 31 - 43